5326372025-07-012025-09-305326372025-09-305326372025-03-315326372025-04-012025-09-305326372025-07-012025-09-30in-capmkt:OtherExpenses1Member5326372025-04-012025-09-30in-capmkt:OtherExpenses1Member5326372025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-07-012025-09-30RelatedPartyTransactionDomain15326372025-06-30RelatedPartyTransactionDomain15326372025-09-30RelatedPartyTransactionDomain15326372025-07-012025-09-30RelatedPartyTransactionDomain25326372025-06-30RelatedPartyTransactionDomain25326372025-09-30RelatedPartyTransactionDomain25326372025-07-012025-09-30RelatedPartyTransactionDomain35326372025-06-30RelatedPartyTransactionDomain35326372025-09-30RelatedPartyTransactionDomain35326372025-07-012025-09-30RelatedPartyTransactionDomain45326372025-06-30RelatedPartyTransactionDomain45326372025-09-30RelatedPartyTransactionDomain45326372025-07-012025-09-30RelatedPartyTransactionDomain55326372025-06-30RelatedPartyTransactionDomain55326372025-09-30RelatedPartyTransactionDomain55326372025-07-012025-09-30RelatedPartyTransactionDomain65326372025-06-30RelatedPartyTransactionDomain65326372025-09-30RelatedPartyTransactionDomain65326372025-07-012025-09-30RelatedPartyTransactionDomain75326372025-06-30RelatedPartyTransactionDomain75326372025-09-30RelatedPartyTransactionDomain75326372025-07-012025-09-30RelatedPartyTransactionDomain85326372025-06-30RelatedPartyTransactionDomain85326372025-09-30RelatedPartyTransactionDomain85326372025-07-012025-09-30RelatedPartyTransactionDomain95326372025-06-30RelatedPartyTransactionDomain95326372025-09-30RelatedPartyTransactionDomain95326372025-07-012025-09-30RelatedPartyTransactionDomain105326372025-06-30RelatedPartyTransactionDomain105326372025-09-30RelatedPartyTransactionDomain105326372025-07-012025-09-30RelatedPartyTransactionDomain115326372025-06-30RelatedPartyTransactionDomain115326372025-09-30RelatedPartyTransactionDomain115326372025-07-012025-09-30RelatedPartyTransactionDomain125326372025-06-30RelatedPartyTransactionDomain125326372025-09-30RelatedPartyTransactionDomain125326372025-07-012025-09-30RelatedPartyTransactionDomain135326372025-06-30RelatedPartyTransactionDomain135326372025-09-30RelatedPartyTransactionDomain135326372025-07-012025-09-30RelatedPartyTransactionDomain145326372025-06-30RelatedPartyTransactionDomain145326372025-09-30RelatedPartyTransactionDomain145326372025-07-012025-09-30RelatedPartyTransactionDomain155326372025-06-30RelatedPartyTransactionDomain155326372025-09-30RelatedPartyTransactionDomain155326372025-07-012025-09-30RelatedPartyTransactionDomain165326372025-06-30RelatedPartyTransactionDomain165326372025-09-30RelatedPartyTransactionDomain165326372025-07-012025-09-30RelatedPartyTransactionDomain175326372025-06-30RelatedPartyTransactionDomain175326372025-09-30RelatedPartyTransactionDomain175326372025-07-012025-09-30RelatedPartyTransactionDomain185326372025-06-30RelatedPartyTransactionDomain185326372025-09-30RelatedPartyTransactionDomain185326372025-07-012025-09-30RelatedPartyTransactionDomain195326372025-06-30RelatedPartyTransactionDomain195326372025-09-30RelatedPartyTransactionDomain195326372025-07-012025-09-30RelatedPartyTransactionDomain205326372025-06-30RelatedPartyTransactionDomain205326372025-09-30RelatedPartyTransactionDomain205326372025-07-012025-09-30RelatedPartyTransactionDomain215326372025-06-30RelatedPartyTransactionDomain215326372025-09-30RelatedPartyTransactionDomain215326372025-07-012025-09-30RelatedPartyTransactionDomain225326372025-06-30RelatedPartyTransactionDomain225326372025-09-30RelatedPartyTransactionDomain225326372025-07-012025-09-30RelatedPartyTransactionDomain235326372025-06-30RelatedPartyTransactionDomain235326372025-09-30RelatedPartyTransactionDomain235326372025-07-012025-09-30RelatedPartyTransactionDomain245326372025-06-30RelatedPartyTransactionDomain245326372025-09-30RelatedPartyTransactionDomain245326372025-07-012025-09-30RelatedPartyTransactionDomain255326372025-06-30RelatedPartyTransactionDomain255326372025-09-30RelatedPartyTransactionDomain255326372025-07-012025-09-30RelatedPartyTransactionDomain265326372025-06-30RelatedPartyTransactionDomain265326372025-09-30RelatedPartyTransactionDomain265326372025-07-012025-09-30RelatedPartyTransactionDomain275326372025-06-30RelatedPartyTransactionDomain275326372025-09-30RelatedPartyTransactionDomain275326372025-07-012025-09-30RelatedPartyTransactionDomain285326372025-06-30RelatedPartyTransactionDomain285326372025-09-30RelatedPartyTransactionDomain285326372025-07-012025-09-30RelatedPartyTransactionDomain295326372025-06-30RelatedPartyTransactionDomain295326372025-09-30RelatedPartyTransactionDomain295326372025-07-012025-09-30RelatedPartyTransactionDomain305326372025-06-30RelatedPartyTransactionDomain305326372025-09-30RelatedPartyTransactionDomain305326372025-07-012025-09-30RelatedPartyTransactionDomain315326372025-06-30RelatedPartyTransactionDomain315326372025-09-30RelatedPartyTransactionDomain315326372025-07-012025-09-30RelatedPartyTransactionDomain325326372025-06-30RelatedPartyTransactionDomain325326372025-09-30RelatedPartyTransactionDomain325326372025-07-012025-09-30RelatedPartyTransactionDomain335326372025-06-30RelatedPartyTransactionDomain335326372025-09-30RelatedPartyTransactionDomain335326372025-07-012025-09-30AuditorDomain15326372025-07-012025-09-30in-capmkt:AuditedMember5326372025-09-30in-capmkt:AuditedMember5326372025-07-012025-09-30in-capmkt:AdjustedMember5326372025-09-30in-capmkt:AdjustedMember5326372025-07-012025-09-30OtherFinancialItemDomain1in-capmkt:AuditedMember5326372025-07-012025-09-30OtherFinancialItemDomain1in-capmkt:AdjustedMember5326372025-07-012025-09-30AuditQualification1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-202025-11-13INRLakhsQuarterlySecond quarterSingle segmentManufacturing of Bulk Drugs2025-11-2012:00:002025-11-2018:00:00trueCash Flow IndirectStatement on impact of audit qualificationtruetrueNANAfalsetrue2025-05-17https://www.mangalamdrugs.com/investors-2/falsefalseNot applicable2025-07-012025-09-30UnauditedStandalone4954410002780004957190002888510001400041732000759130005028200045335000117260000619387000-1236680000-1236680002876000-54080000-512040000-724640000000-72464000-1458000-7392200015828200010-4.58-4.5800-4.58-4.581. The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. <BR> 2. The above unaudited standalone financial results of the Company for the Quarter and Half year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on November 20,2025. Statutory auditors have carried Limited Review for the quarter and half year ended on that date. <BR> 3. The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. <BR> 4.The figures for the quarter ended 30th September, 2025 are the balancing figures between the figures in respect of half year ended 30th September, 2025 and the unaudited published figures for the quarter ended 30th June 2025. <BR> 5. The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon’ble National Company Law Tribunal. The final hearing for the same is scheduled on 16th December 2025. <BR> 6. During the quarter, the Company has recognized deferred tax asset on tax losses based on the projection available with the Company as on date which will be reviewed at the end of the year. <BR> 7. Other Expenses <BR> Rs in Lakhs <BR> Particulars Quarter Ended Half Year Ended Year Ended <BR> 30.09.2025 30.06.2025 30.09.2024 30.09.2025 30.09.2024 31.03.2025 <BR> Unaudited Unaudited Unaudited Unaudited Unaudited Audited <BR> Power and <BR> Fuel Expenses 437.32 446.30 842.35 883.62 1,453.18 2,788.18 2025-04-012025-09-30UnauditedStandalone106892800028200010692100005221880001400020418500016903800090727000891440002468620001322158000-2529480000-2529480002876000-46080000-432040000-2097440000000-209744000-2600000-21234400015828200010-13.25-13.2500-13.25-13.25Other Expenses117260000Other Expenses2468620001074057000354990000026821600031026000034500000034500001603350001569478000116935000001702030003289700001078500063174000277059000080627000152703600000309651400015828200011159350001274217000127421700011312200000001131220000511990000403430002046640007776760007311100054385400061696500041759000143640000017243900087880006000016176330000018222970003096514000907270002186680002205260000279660000153100000-2961940000377920000891440000-166200000-13033000-276090000400000-35660000000032932800076380000000007638000000000000-377000-5796600000000000000000000-40000005758500000000000790960000009072700000-11631000122334000716400012949800025733000155231000Other comprehensive income [Abstract]-1458000-1458000Other comprehensive income [Abstract]-2600000-26000000000-1458000-2600000Mangalam Drugs and Organics Limited******Raga Organics Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent received100000Not Applicable300060003000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAdvance300000000Not Applicable9817000237503000227686000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent received500000000Not Applicable150003600015000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionLegal/Technical/ Proefessional fees325000Not Applicable01100000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorPurchase of goods or services100000000Not Applicable050530000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorSale of goods or services100000000Not Applicable0407700000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAny other transactionCommission paid on sales2000000Not Applicable168700001687000Mangalam Drugs and Organics Limited******Rakesh Milwani******Non-Executive DirectorAny other transactionSitting fees100000Not Applicable8000160008000Mangalam Drugs and Organics Limited******Mrs. Nidhi Mundada******Non-Executive DirectorAny other transactionSitting fees100000Not Applicable200004200022000Mangalam Drugs and Organics Limited******Mr. Rukmesh Dhandhania******Non-Executive DirectorAny other transactionSitting fees100000Not Applicable200003600016000Mangalam Drugs and Organics Limited******Mr. Praveen Saxena******Non-Executive DirectorAny other transactionSitting fees100000Not Applicable120002400012000Mangalam Drugs and Organics Limited******Ms. Anauradha Pandey******Company SecretaryAny other transactionSalary2000000Not Applicable566000631000566000Mangalam Drugs and Organics Limited******Govardhan M. Dhoot******Chairman & Managing Director (KMP)Remuneration5000000Not Applicable100000020170001000000Mangalam Drugs and Organics Limited******Brijmohan M. Dhoot******Executive DirectorRemuneration600000Not Applicable300000617000300000Mangalam Drugs and Organics Limited******Mr. Ajay Samant******Chief Financial OfficerAny other transactionSalary3000000Not Applicable144200028840001442000Mangalam Drugs and Organics Limited******Mrs. Rekha G. Dhoot******Promoter groupAny other transactionSalary3000000Not Applicable146200029420001462000Mangalam Drugs and Organics Limited******Mrs. Jyoti B. Dhoot******Promoter groupAny other transactionSalary3000000Not Applicable146200029420001462000Mangalam Drugs and Organics Limited******Ms. Shweta G. Dhoot******Promoter groupAny other transactionSalary1000000Not Applicable433000883000433000Mangalam Drugs and Organics Limited******Mrs. Krishnapriya Nawal******Relative of KMPAny other transactionSalary3000000Not Applicable123600029850001236000Mangalam Drugs and Organics Limited******Mrs. Radhika A Dhoot******Promoter groupAny other transactionSalary2000000Not Applicable7330001484000733000Mangalam Drugs and Organics Limited******Mrs. Smita A. Dhoot******Promoter groupAny other transactionSalary2000000Not Applicable7330001484000733000Mangalam Drugs and Organics Limited******Mr. Yaduraj A. Dhoot******Relative of KMPAny other transactionSalary4000000Not Applicable204800037210002048000Mangalam Drugs and Organics Limited******Ms. Mahima A. Dhoot******Relative of promoter groupAny other transactionSalary5000000Not Applicable204800041130002065000Mangalam Drugs and Organics Limited******Ms. Kripa Saraf******Relative of promoter groupAny other transactionLegal / Professional /Tech.fees2000000Not Applicable8480001491000643000Mangalam Drugs and Organics Limited******Ajay Samant******Chief Financial OfficerAny other transactionTermination Benefit100000Not Applicable021830000Mangalam Drugs and Organics Limited******Anuradha Pandey******Company SecretaryAny other transactionTermination Benefit100000Not Applicable250003200025000Mangalam Drugs and Organics Limited******Mrs. Rekha G. Dhoot******Promoter groupAny other transactionTermination Benefit70000Not Applicable290005800029000Mangalam Drugs and Organics Limited******Mrs. Jyoti B. Dhoot******Promoter groupAny other transactionTermination Benefit70000Not Applicable290005800029000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAny other transactionrent paid500000Not Applicable210000420000210000Mangalam Drugs and Organics Limited******Shweta Dhoot******Promoter groupAny other transactionTermination Benefit20000Not Applicable9000170009000Mangalam Drugs and Organics Limited******Krishnapriya Dhoot******Promoter groupAny other transactionTermination Benefit80000Not Applicable260006300026000Mangalam Drugs and Organics Limited******Govardhan M. Dhoot******PromoterAny other transactionRent deposit1000000Not Applicable07000000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent deposit100000Not Applicable05000026221000UnauditedQualified opinionM/s.V . S. SOMANI & CO.true2027-07-3100000000000000Tax expensesTax expenses00We draw attention to Note 6 of the accompanying Statement. which states that the Company has recognized Deferred Tax Assets (DTA) on tax losses for the quarter and half year ended 30 September 2025 based on the projections of probable future taxable profit prepared by the management which will be subject to audit.Qualified opinionWhether appeared first timeDuring the quarter, the Company has recognized deferred tax asset on tax Tosses based on the projection available with the Company as on date which will be reviewed at the end of the year.During the quarter, the Company has recognized deferred tax asset on tax Tosses based on the projection available with the Company as on date which will be reviewed at the end of the year.During the quarter, the Company has recognized deferred tax asset on tax Tosses based on the projection available with the Company as on date which will be reviewed at the end of the year.We draw attention to Note 6 of the accompanying Statement. which states that the Company has recognized Deferred Tax Assets (DTA) on tax losses for the quarter and half year ended 30 September 2025 based on the projections of probable future taxable profit prepared by the management which will be subject to audit.GOVARDHAN M. DHOOTGOVARDHAN M. DHOOTNIDHI MUNDADAVIDYADHAR SOMANIMUMBAI2025-11-20